O

Oncoinvent ASA
OSE:ONCIN

Watchlist Manager
Oncoinvent ASA
OSE:ONCIN
Watchlist
Price: 0.462 NOK -0.65% Market Closed
Market Cap: 206.5m NOK

Relative Value

The Relative Value of one ONCIN stock under the Base Case scenario is hidden NOK. Compared to the current market price of 0.462 NOK, Oncoinvent ASA is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ONCIN Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
76
vs Industry
Median 3Y
10 123
Median 5Y
33 768.6
Industry
2.7
Forward
15.4
vs History
vs Industry
Median 3Y
-29.9
Median 5Y
-56.1
Industry
21.6
Forward
-0.4
vs History
vs Industry
Median 3Y
-27.7
Median 5Y
-53.1
Industry
16.9
vs History
vs Industry
Median 3Y
-27.7
Median 5Y
-53.1
Industry
22.9
vs History
53
vs Industry
Median 3Y
29.8
Median 5Y
97.5
Industry
2.3
vs History
76
vs Industry
Median 3Y
9 738.9
Median 5Y
33 326.7
Industry
3
Forward
10.2
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.6
vs History
vs Industry
Median 3Y
-27.3
Median 5Y
-54
Industry
13.4
Forward
-1.2
vs History
vs Industry
Median 3Y
-27.2
Median 5Y
-53.9
Industry
16.7
Forward
-1.1
vs History
vs Industry
Median 3Y
-26.6
Median 5Y
-52.4
Industry
16.1
vs History
vs Industry
Median 3Y
-26.6
Median 5Y
-52.4
Industry
18.9
vs History
76
vs Industry
Median 3Y
39.3
Median 5Y
-2 031.2
Industry
2

Multiples Across Competitors

ONCIN Competitors Multiples
Oncoinvent ASA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
NO
Oncoinvent ASA
OSE:ONCIN
206.5m NOK 38.2 -1.9 -1.2 -1.2
US
Eli Lilly and Co
NYSE:LLY
1T USD 17 54.8 36.7 39.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
518.3B USD 5.6 20.6 16.8 21.8
CH
Roche Holding AG
SIX:ROG
274.2B CHF 4.5 29.1 12.4 14.4
UK
AstraZeneca PLC
LSE:AZN
221.2B GBP 5.1 31.4 108.8 159.2
CH
Novartis AG
SIX:NOVN
222.3B CHF 4.9 19.3 12.2 15.7
US
Merck & Co Inc
NYSE:MRK
269.8B USD 4.2 14.1 10 11.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.3 16.2 11.3 13.1
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
143.7B USD 2.3 14.6 7.5 10.2
P/E Multiple
Earnings Growth PEG
NO
O
Oncoinvent ASA
OSE:ONCIN
Average P/E: 25
Negative Multiple: -1.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.8
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.6
29%
0.7
CH
Roche Holding AG
SIX:ROG
29.1
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.4
37%
0.8
CH
Novartis AG
SIX:NOVN
19.3
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.1
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
16.2
3%
5.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NO
O
Oncoinvent ASA
OSE:ONCIN
Average EV/EBITDA: 440.1
Negative Multiple: -1.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.7
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.8
9%
1.9
CH
Roche Holding AG
SIX:ROG
12.4
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
CH
Novartis AG
SIX:NOVN
12.2
6%
2
US
Merck & Co Inc
NYSE:MRK
10
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.3
1%
11.3
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NO
O
Oncoinvent ASA
OSE:ONCIN
Average EV/EBIT: 1 883.7
Negative Multiple: -1.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.4
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.8
15%
1.5
CH
Roche Holding AG
SIX:ROG
14.4
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.2
23%
6.9
CH
Novartis AG
SIX:NOVN
15.7
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.9
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
13.1
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5